Dr. Phillip Chappell is Senior Director, Neuroscience Specialty Therapeutics for Pfizer. He is board certified in both General Psychiatry and in Child and Adolescent Psychiatry. He earned his medical degree from the University of North Carolina School of Medicine. Following a residency at Duke University Medical Center, Dr. Chappell completed fellowship training in both clinical research and Child and Adolescent Psychiatry at the Yale School of Medicine. He then joined the faculty of the Yale Child Study Center, where he served as Associate Director of the Child Psychiatric Inpatient Service. Dr. Chappell has experience diagnosing and treating children with Autism, Tourette’s Syndrome, ADHD, and Obsessive Compulsive Disorder and conducting clinical research and pediatric clinical trials. He continues to maintain an appointment as Assistant Clinical Professor in Child and Adolescent Psychiatry at the Yale Child Study Center.
Dr. Chappell joined Pfizer as a member of the Early Clinical Research Group. In this role, he was involved in the early clinical development of a wide range of central nervous system compounds covering all the major psychiatric and neurologic conditions. He subsequently provided clinical leadership for programs in depression, insomnia, psychosis, bipolar disorder, and ADHD, among others.